Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D.
Thummuri D, et al. Among authors: trevino jg.
Mol Cancer Ther. 2022 Jan;21(1):184-192. doi: 10.1158/1535-7163.MCT-21-0474. Epub 2021 Oct 19.
Mol Cancer Ther. 2022.
PMID: 34667112
Free PMC article.